MindMed (NASDAQ: MNMD)

Atai Life Sciences

This biopharmaceutical company develops psychedelic and non-psychedelic therapies for patients living with mental health disorders, including depression, anxiety, and addiction.

ATAI

This biopharmaceutical company develops psychedelic-based treatments and mental health medicines for patients with neurological and psychiatric disorders, such as treatment-resistant depression and anxiety.

Mycrodose Therapeutics

This pharmaceutical company develops advanced drug delivery systems for psychedelic and cannabinoid compounds to treat mental health and cognitive degenerative diseases.

Small Pharma Limited

This clinical-stage biotechnology company develops psychedelic-based medicines and DMT therapies for patients with major depressive disorder and other mental health conditions.

Mindstate Design Labs

This biotechnology company develops custom psychedelic therapeutics using an artificial intelligence platform to treat mental health conditions for patients with various psychiatric disorders.

GH Research

This pharmaceutical company develops psychedelic-based therapies for patients suffering from psychiatric and neurological disorders, including treatment-resistant depression.

Reunion Neuroscience

This biopharmaceutical company develops psychedelic-inspired therapeutic solutions for patients with underserved mental health disorders, such as postpartum depression and anxiety.

Compass Pathways

This biotechnology company develops psilocybin-based therapies for patients living with treatment-resistant depression and other mental health conditions.